PCSA — Processa Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1533743 ·
Last close
$2.15
Market Cap
$5.95M
52W High
$3.38
52W Low
$1.67
ADV30
443,477
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,331,214 | -3,377,179 | 4,520,974 | 1,691,043 | 1,980,093 |
| Dec 2025 | 0 | — | -3,701,889 | -3,358,938 | 7,813,567 | 5,536,955 | 2,236,253 |
| Sep 2025 | 0 | — | -3,488,843 | -3,436,573 | 7,584,576 | 6,308,420 | 1,750,978 |
| Jun 2025 | 0 | — | -3,950,783 | -3,933,918 | 8,181,789 | 6,936,620 | 2,074,581 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,385,195
Investing CF
$-850,000
Financing CF
$16,580,825
CapEx
—
Dividends Paid
—
Buybacks
$-10,404
EPS Diluted TTM
$-41.25
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-100,783,033
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-13,988,505
Pretax Income TTM
$-13,563,834
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,988,505 | -13,563,834 | 7,813,567 | 2,236,253 | — | -11,385,195 |
| Dec 2024 | 0 | -12,051,206 | -11,850,118 | 3,229,289 | 1,533,118 | — | -11,245,042 |
| Dec 2023 | 0 | -11,457,061 | -11,121,520 | 5,786,643 | 797,484 | — | -8,063,346 |
| Dec 2022 | 0 | -20,257,288 | -27,424,229 | 8,619,851 | 1,149,110 | — | -9,605,143 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.75
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CURX | Curanex Pharmaceuticals Inc | $5.81M | $0.20 | — |
| XBIO | Xenetic Biosciences, Inc. | $5.81M | $2.54 | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $5.74M | $0.44 | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $6.19M | $1.44 | — |
| CVKD | Cadrenal Therapeutics, Inc. | $6.23M | $2.01 | — |
News headlines (Yahoo Finance, 1h cache)
Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline
2026-07-29 14:33 · Yahoo
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA
2026-07-29 11:30 · Yahoo
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
2026-01-12 14:15 · Yahoo
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-01-09 14:00 · Yahoo
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
2026-01-05 14:15 · Yahoo
Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2025-12-26 14:00 · Yahoo
Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
2025-12-18 14:23 · Yahoo
Top Midday Gainers
2025-12-17 18:37 · Yahoo
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
2025-12-17 13:00 · Yahoo
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?
2025-12-17 10:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.